“…Psychiatric disorders are no exception in the quest to use TSPO as a biomarker of neuroinflammation and the last 5 years have seen a number of reports with mixed results [see review by De Picker et al, 2017]. Paradoxically, some studies have provided the first description of decreased rather than increased brain TSPO levels in schizophrenia [Coliste et al, 2017;Benlloch et al, 2018] and in major depression [Li et al, 2018]. Overall, studies have found increased, decreased, or no change in brain TSPO levels in schizophrenia [De Picker et al, 2017] and in depression [Hannestad et al, 2013;Setiawan et al, 2015;Holmes et al, 2017;Li et al, 2018;Richards et al, 2018;Setiawan et al, 2018] compared to age-matched controls using PET imaging with radiolabeled R-PK11195 or with second generation TSPO PET ligands.…”